Nothing Special   »   [go: up one dir, main page]

WO2022180447A1 - Procédé d'élimination de micro-organismes pathogènes spécifiques dans le corps - Google Patents

Procédé d'élimination de micro-organismes pathogènes spécifiques dans le corps Download PDF

Info

Publication number
WO2022180447A1
WO2022180447A1 PCT/IB2022/000017 IB2022000017W WO2022180447A1 WO 2022180447 A1 WO2022180447 A1 WO 2022180447A1 IB 2022000017 W IB2022000017 W IB 2022000017W WO 2022180447 A1 WO2022180447 A1 WO 2022180447A1
Authority
WO
WIPO (PCT)
Prior art keywords
microorganisms
expression
oxidation
enos
human body
Prior art date
Application number
PCT/IB2022/000017
Other languages
English (en)
Inventor
Joachim Hochreuter
Original Assignee
Joachim Hochreuter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/182,664 external-priority patent/US20220133625A1/en
Application filed by Joachim Hochreuter filed Critical Joachim Hochreuter
Publication of WO2022180447A1 publication Critical patent/WO2022180447A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals

Definitions

  • the present invention relates to a method for eliminating selected microorganisms of one or several types within the human body and, more particularly, to a combined method for eliminating microorganisms within the human body that requires a mechanical pre-damage of the pathogens capsule, secondly intake of a safe dose of an external oxidant, plus parallel supplements that invoke controlled eNOS-expression (ROS/RNS) for a determined time, as a result producing internal radical oxidation/nitric species in the body.
  • ROS/RNS controlled eNOS-expression
  • the method further includes a second step including penetrating the damaged hulls of the pathogens with a safe dose of an external and parallel internal produced oxidation species to eliminate the microorganism.
  • the external oxidation product may include chlorine dioxide in a watery solution (at a dose generally recognized as safe).
  • the internally oxidation product is produced inside of the body as ROS (radical oxygen/oxide species), and/or RNS (radical nitrogen/nitric species), this results in a shifting of uncontrolled NO gas production from iNOS(induced Nitric Oxide Synthase) - expression towards controlled NO gas production from eNOS (endothelial Nitric Oxide Synthase) - expression.
  • eNOS-expression is capable to do the oxidation effect on the damaged hulls of the damaged microorganisms.
  • This new method uses the intentional invoked eNOS-expression (using Vitamins B2,B3,B9,Zn Zinc, Fe Iron, and amino acids L- Arginine and L-Citruline) as a tool to reduce the free radicals in the body such as the dangerous Superoxide 0-, Peroxynitrite ONOO-, Dinitro-trioxide N203 radicals, which would cause damage to the human cells if uncontrolled NO (Nitric Oxide) production is invoked from macrophages, or neutrophilic granulocytes or inflammatory interleukines causing iNOS-expression with 1000 times the NO production as in eNOS-expression.
  • eNOS-expression using Vitamins B2,B3,B9,Zn Zinc, Fe Iron, and amino acids L- Arginine and L-Citruline
  • the vitamins B2 (Riboflavine), B3 (Niacine), B9 (Folic Acid) [actually a derivate from vitamin B9 which is called BH4 “Tetrahydrobiopterin” and is formed from vitamin B9 inside of the body] are required for the donation of electrons in this biochemical process, it forms BH3+ and is recycled to BH4.
  • Zinc forms with a Hem (iron) group a so called “dimere” which is required for eNOS-expression.
  • Oxygen as 02 will react in this systems to donate Oxygen, forming NO gas and the B-vitamins electrons e- which are absorbed from receptors of the L- Arginine and forming NO Nictric Oxide as a gas and L-Citruline aminoacid as the reaction products.
  • the NO as a gas is the internal oxidation product we used.
  • the L-Citruline is recycled to L-Arginine.
  • the method further includes a third step terminating and reducing the two different oxidation processes by providing antioxidants in form of Vitamin C and Vitamin E to neutralize the external oxidant CL02 within 20 minutes.
  • TH2 is the antagonist for ROS/RNS production or TH1 dominance. So if the shifting towards TH2 is initiated the production of the internal NO gas using eNOS-expression or ROS/RNS radical species is reduced, stopping the internal oxidation process and activating the TH2 of the immune system, leading to the increased production of antibodies and the application of B-cells of the immune systems defense.
  • a fourth step includes determining deficiencies within the body using a NLS system or laboratory blood analysis and supplementing the missing elements selectively according to the deficiencies encountered, thereby strengthening the immune system by providing the missing educts for biochemical reactions, such supplements as essential amino acids in an aqueous solutions as well as, vitamins, minerals, trace-elements and co-enzymes etc. to the human body.
  • Applicant believes that a related reference corresponds to U.S. patent No. 7,165,451 issued for a detection of inorganic acid and biologic structures using resonant acoustic and/or resonant acoustic-EM energy. Applicant believes that another related reference corresponds to U.S. patent No. 5,658,322 issued for a system and method for generating bio-active frequencies. The generated frequencies are used to advantage in health science applications such as killing microorganisms and viruses and enhancing tissue generation.
  • the cited references differ from the present invention because they fail to evenly destroy different sizes of the same present pathogen type, to disclose the combination of using resonant frequency treatment to pre-damage the hull of a pathogen and then introducing an oxidation step to eliminate a specific type of pathogen. None of them is capable to bring inflammations, thrombus, edemas caused from iNOS-expression under control, with its dramatic damaging effects inside of the body, nor do they explicitly strengthen the immune system to take over control again after the treatment.
  • the viruses are oxidized in a way so they cannot multiply anymore.
  • a further object of this invention is the intentional stop of the oxidation process and invoking TH2 shifting leading to the increased production of antibodies of the immune system and B- cells to fight the pathogens.
  • Figure 1 represents a flow chart for a method 10 including a first step 20, a second step 40, a third step 60 and a fourth step 80 in accordance to an embodiment of the present invention.
  • a method 10 for eliminating selectively microorganisms which basically include a first step 20, a second step 40, a third step 60, and a fourth step 80.
  • First step 20 includes measuring frequencies of pathogens and applying a varying resonance frequency to the pathogens according to existing different sizes etc. This step is accomplished through an analytic electronic method with electrodes.
  • the electrodes emit DC current induced at discrete frequencies by stepping up in discrete selected steps within a frequency band, offering vibration energy to the pathogens. If resonance is offered and achieved for a certain pathogen it is able to start to vibrate using this offered energy at a maximum amplitude. It is then measured the frequency that results resonance and how much energy is absorbed from these pathogens that start to vibrate at this specific resonance frequency. This physical effect is known as prior art in the field of resonant frequencies and pathogens.
  • Every microorganism of a specific type and size has a discrete resonance frequency and will vibrate in its first harmonic resonance frequency form at maximum amplitude, in the present method, if an electromagnetic wave or current is applied at this resonance frequency.
  • the offered vibrations energy which is applied to provide a certain level of intensity is partially absorbed by the microorganism and transformed into heat and further into mechanical fatigue in the hull/capsule. If the vibrations are applied long enough the capsule of the microorganism will even rupture. This damage effect is known as “fatigue”.
  • a variable resonant frequency band should therefore be applied to the pathogens to evenly fatigue all of the pathogens. This effect can be applied to the pathogens until the microorganism eventually explode and everything within the microorganism is released and the microorganisms will eventually die.
  • the present invention utilizes this fatigue effect; however, the fatigue effect is only applied to produce a small defect in the hull in form of a pre damage/crack/weakness, which is sufficient if combined with the second oxidation step to destroy the pathogen. The fatigue effect is not used to completely destroy the microorganisms hull or capsule at this step.
  • Human cells are known to have a resonant frequency around eight million Hertz and microorganisms and pathogens are known to have a resonant frequency mostly below 2 million Hertz. As a result, no damage is done to human cells during the process of applying the resonant frequencies to the microorganisms and pathogens.
  • a frequency of 200,000 Hertz using discrete steps of 1000 Hertz for detecting the resonance frequency of a microorganism. It is known that the human body may contain a large number of different microorganisms therein and that in order for a disease to develop symptoms or illness a certain threshold of microorganisms need to be exceeded.
  • a peak of absorption of energy indicates the presence of a big amount of the same microorganism type even though the immune system is fighting to control it.
  • the threshold depends on the type of microorganism and symptoms/illness level.
  • a relation is made as to the resonant frequency of the microorganisms and the illness/symptoms.
  • a standard frequency generator is used to generate a frequency band which is half of the discrete step width (here it was 1000 Hz steps), so from +- 500 Hertz around the measured absorption frequency.
  • the frequency generator begins at 199,500 Hertz and steps up to 200,500 Hertz, by stepping up every second by 1 Hertz. One complete stepping up and down is called a cycle.
  • the frequency generator is attached to an antenna or contact electrodes which apply a maximum of 15 VDC output.
  • the antenna or contact electrodes are applied to a patient and the process is repeated several times/cycles to produce small defects/cracks/weaknesses in the hulls of microorganisms, but sufficiently profound. This process takes considerably less time than attempting to completely rupture all the different sized cells of the microorganisms using only this process.
  • Second step 40 includes penetrating the damaged hulls of the microorganism with a low dose of an ingested external oxidation product and an oxidation product generated inside the body as an eNOS-expression (ROS /RNS).
  • ROS /RNS an eNOS-expression
  • the present method provides a solution to the problems involved in the use of disinfection products.
  • the present invention applies a very low dose of an external ingested disinfection product plus, in parallel invokes internal oxidation / nitric species being produced, known as eNOS-expression, towards the fatigued hulls of the microorganisms and thereby selectively destroys them preferably easier due to the crack or damage or local weakness in the capsule.
  • eNOS-expression internal oxidation / nitric species being produced
  • the double lipid membrane of the microorganisms is more easily penetrated due to their fatigued/weakened nature and allows for oxidation to take place for the guanine of the ARN (ribo nuclein acid) or ADN (desoxiribo nuclein acid) of the microorganism.
  • the microorganisms of a virus do not have a cellular core nor a metabolism of its own.
  • the viral microorganisms contain ADN or ARN within the cellular hull which need to invade a human cell in order to reproduce. Additionally, both the ADN and ARN of the microorganisms include a guanine base.
  • the present invention utilizes external ingestion of chlorine dioxide (CI02) in a watery solution and eNOS-expression to change the guanine base into a guanine- oxidized base.
  • the present invention introduces chlorine dioxide (CI02) in an aqueous solution of 0.75 ppm (which is below 0,8 ppm, which is generally recognized as safe by the FDA). 5 drops of 3000- ppm chlorine dioxide (CI02) are given to 1 liter of water resulting in 0.75 ppm drinkable solution. 1 ccm of 3000 ppm equals 20 drops or 3 mg, so 5 drops give a 0.75 mg/ltr or 0.75 ppm concentration.
  • first step 20, second step 40, a third step 60 and a fourth step 80 may be used in different cases to eliminate SARS-CoV 2 and control Covid-19.
  • the antenna or electrodes cycle the measured and programmed resonance frequencies by stepping up and stepping down several cycles that are applied to the human body, the external oxidation is done in a way of drinking every 30 minutes a glass of water containing 0.75 ppm C102 in watery solution.
  • the eNOS expression is started at the same time, by supplementing the following listed products at the same time, this is ingested together with the CL02 in watery solution:
  • Vitamin B3 (NAD, Niacine)
  • Vitamin B9 Fralic acid
  • 5-MTHF 5-Methyl Tetra Hydro Folate
  • Vitamin B2 (Riboflavine)
  • Vitamin B3 (NAD, Niacine),
  • Vitamin B9 Fralic acid
  • 5-MTHF 5-Methyl Tetra Hydro Folate
  • L-Citruline-Malate (amino acid), a product from eNOS- expression bio-chemical reaction (besides the NO), reduces iNOS and brings NO hyperexpression and the high radical production of superoxide 0-, peroxinitrite ONOO- and dinitro-trioxide N203 back under control.
  • Method 10 further includes a third step 60 which involves terminating the oxidation process, which was initiated from second step 40 by a way of introducing antioxidants using Vitamin E (800 i.U), Vitamin C (500 mg), to stop the oxidation of the CL02 external oxidation product.
  • Vitamin E 800 i.U
  • Vitamin C 500 mg
  • method 10 includes inducing the oxidation effect during the day and terminating the oxidation effect latest at night, half an hour before the patient goes to bed.
  • steps 20 and 40 are applied. As soon as the symptoms of Covid-19 reduce, the ingestion of external C102 in watery solution and the eNOS expression is still kept up for another 2 hours, as described above. If the treatment was intended to be done and the patient did not show any symptoms but was positively tested on SARS-CoV2, then step 20 and 40 is sustained for max. 3 hours as a preventive measure to show the effect of eliminating the SARS-CoV2 and preventing Covid-19. Afterwards, after another hour after the last intake of the oxidation products, step 60 is activated using antioxidants and TH2 shifting.
  • the products that work for step 60 are a combination of Vitamin E, Vitamin C, Glutathion amino acid, MnSOD (Manganese Super Oxide Dismutase, supplementing the metal manganese, MnSOD is produced in the body) in form of Mn gluconate, and ZnSOD (Zinc Super Oxide Dismutase, supplementing the zinc, ZnSOD is produced in the body) in form of Zn gluconate.
  • MnSOD Manganese Super Oxide Dismutase, supplementing the metal manganese, MnSOD is produced in the body
  • ZnSOD Zinc Super Oxide Dismutase, supplementing the zinc, ZnSOD is produced in the body
  • Antibodies are proteins, which are synthesized in the lymph cells using amino acids.
  • the 20 amino acids used contain 8 essential and 12 non-essential amino acids.
  • the 12 non- essential amino acids can be synthesized inside the body if sufficient essential amino acids, minerals, vitamins, co-enzymes trace-elements and co-factors are available.
  • a low protein diet can lead to these amino acid deficiencies.
  • vegan or vegetarian diets lead to a depletion of B-Vitamins etc. Doing no exercise or no sports leads to a low level of antioxidants leading to eNOS uncoupling due to the lack of free radical neutralization.
  • Parasites might lead to depletion of available metals (iron, hemoglobin, and zinc etc) and vitamins/minerals etc. in the body for bio-chemical reactions and might lead to the blockage of available L-Arginine to prevent their own destruction from eNOS expression (using elevated Arginase release).
  • a lack of L-Arginine causes eNOS-uncoupling and iNOS-expression as well as the production of dangerous Superoxide and Peroxinitrite and Dinitro-Trioxide.
  • ADMA asymmetric di methyl arginine
  • Method 10 may be implemented for various applications and is not limited to SARS-CoV 2, Corona Virus.
  • Other applications include using method 10 on cases of Herpes, Dengue, Malaria and other known microorganisms, in special antibiotic resistant or even multi -resistant pathogens or even in case of mutations where successful vaccines are not effective anymore. This is especially important in respect to Covid-19, because vaccines only protect to a certain point and with the present method people that get infected after the vaccination can be detoxified from SARS-Cov2. New mutations of the virus can also easily be eliminated, adopting if necessary the frequency band. The virus has no chance to escape the mechanical fatigue and the chemical oxidation process.
  • Method 10 allows a user to target any specific microorganism and eliminate them using the oxidation process, together with the resonance frequencies and combined oxidation steps, the intentional stop of the oxidation process and then activating of TH2 shifting (and the production of antibodies and B-cells) and finally the strengthening of the immune system supplementing the missing educts.
  • the method for eliminating microorganisms has several embodiments for industrial applicability.
  • the method allows a medical practitioner to selectively target pathogen types to be eliminated while leaving the good microorganisms unharmed.
  • the medical practitioner may take control over inflammations associated with aggregation of thrombocytes that leads to thrombus, edemas and sepsis caused by NO poisoning or iNOS-expression with the high liberation of peroxinitrite ONOO-superoxide O- and dinitro-tri oxide N203.
  • the method is capable of eliminating pathogens of the same population but that may vary in size, length, diameter, and age efficiently and much faster than other methods with far less side effects.
  • the method for eliminating microorganisms is capable of leaving non-threatening microorganisms untouched independent of apparatus producers or producers of the chemical watery solution of C102 or supplements like essential amino acids, vitamins, minerals, trace-elements and co-enzymes etc..
  • the method provides a synergetic effect that only the disclosed steps of the method provide.
  • the invoked eNOS expression using L-Citruline leads to the possibility to take control caused by an eNOS -uncoupling leading to iNOS-expression, hyper inflammation, aggregation of thrombocytes leading to thrombus and edemas and sepsis, caused by a 1000 times production of NO, superoxide O-, peroxinitrite ONOO- and dinitro-trioxide N203.
  • the method intentionally stops the oxidation process and the invocation of the TH2 shift that leads to the increased production of antibodies of the immune system and B -cells to fight the pathogens.
  • the method for eliminating microorganisms allows to selectively neutralize pathogens.
  • the method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly.
  • the method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS).
  • the external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression.
  • the method further includes a third step to deliberately terminating the activated oxidation processes.
  • a fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Le procédé d'élimination de micro-organismes permet de neutraliser sélectivement des pathogènes. Le procédé comprend une première étape qui consiste à mesurer les fréquences d'agents pathogènes à l'intérieur d'un corps humain qui sont à une forte population présente, conduisant à d'autres maladies ou symptômes. Les pathogènes de taille différente sont ensuite appliqués à une bande de fréquence de résonance pour pré-endommager/craquer/affaiblir les coques des micro-organismes de façon régulière. Le procédé comprend en outre une seconde étape consistant à rompre les coques endommagées des pathogènes ou l'oxydation de l'ARN/ADN dans le cas d'un virus avec une dose sûre d'un produit d'oxydation externe conjointement avec l'expression de eNOS produite interne (ROS/RNS). Le produit externe peut comprendre du dioxyde de chlore dans une solution aqueuse de 0,75 ppm, des vitamines, des minéraux et des acides aminés pour démarrer l'expression de eNOS. Le procédé comprend en outre une troisième étape pour terminer volontairement les procédés d'oxydation activés. Une quatrième étape renforce le système immunitaire par le remplissage de niveaux appauvris de vitamines, de minéraux et d'acides aminés.
PCT/IB2022/000017 2021-02-23 2022-01-19 Procédé d'élimination de micro-organismes pathogènes spécifiques dans le corps WO2022180447A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/182,664 2021-02-23
US17/182,664 US20220133625A1 (en) 2020-07-13 2021-02-23 Method for eliminating specific pathogenic microorganisms in the body

Publications (1)

Publication Number Publication Date
WO2022180447A1 true WO2022180447A1 (fr) 2022-09-01

Family

ID=80684886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/000017 WO2022180447A1 (fr) 2021-02-23 2022-01-19 Procédé d'élimination de micro-organismes pathogènes spécifiques dans le corps

Country Status (1)

Country Link
WO (1) WO2022180447A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714027A2 (fr) * 1994-11-23 1996-05-29 5E Systeme für holistische Medizin Ges.m.b.H. Appareil et méthode pour enregistrer de l'information spécifique à des substances et au corps
US5658322A (en) 1995-10-11 1997-08-19 Regeneration Technology Bio-active frequency generator and method
US7165451B1 (en) 1998-09-11 2007-01-23 Gr Intellectual Reserve, Llc Methods for using resonant acoustic and/or resonant acousto-EM energy to detect and/or effect structures
RU66205U1 (ru) * 2007-02-16 2007-09-10 Анатолий Филиппович Подкопаев Устройство для генерирования группы импульсов спектра частот
DE202009006244U1 (de) * 2009-04-30 2009-07-16 Baklayan, Alan Bioresonanzgerät

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714027A2 (fr) * 1994-11-23 1996-05-29 5E Systeme für holistische Medizin Ges.m.b.H. Appareil et méthode pour enregistrer de l'information spécifique à des substances et au corps
US5658322A (en) 1995-10-11 1997-08-19 Regeneration Technology Bio-active frequency generator and method
US7165451B1 (en) 1998-09-11 2007-01-23 Gr Intellectual Reserve, Llc Methods for using resonant acoustic and/or resonant acousto-EM energy to detect and/or effect structures
RU66205U1 (ru) * 2007-02-16 2007-09-10 Анатолий Филиппович Подкопаев Устройство для генерирования группы импульсов спектра частот
DE202009006244U1 (de) * 2009-04-30 2009-07-16 Baklayan, Alan Bioresonanzgerät

Similar Documents

Publication Publication Date Title
Lisi et al. Nitric oxide to fight viral infections
JP2010051963A (ja) 高濃度水素溶存水を含有する飲料
Prentice Iron metabolism, malaria, and other infections: what is all the fuss about?
JP2005126384A (ja) 薬理機能水、およびその用途
EP2289496A3 (fr) Systeme de capsule molle non gelatineux
WO2003002466A1 (fr) Procede d'antioxydation et eau a fonction antioxydante
WO2007010422A3 (fr) Appareil et methode permettant de detecter des impulsions de defibrillation a l'aide d'ondes electromagnetiques
US20100008850A1 (en) Method of generating hydrogen in drinking water using an enerceutical product added to magnesium in a hydrogen permeable but solute impermeable container
Gurton et al. Sodium bicarbonate ingestion improves time-to-exhaustion cycling performance and alters estimated energy system contribution: a dose-response investigation
Bell et al. Nonlinear response amplification mechanisms for low doses of natural product nanomedicines: dynamical interactions with the recipient complex adaptive system
US20220133625A1 (en) Method for eliminating specific pathogenic microorganisms in the body
WO2022180447A1 (fr) Procédé d'élimination de micro-organismes pathogènes spécifiques dans le corps
Van Buiten et al. Elemental iron modifies the redox environment of the gastrointestinal tract: a novel therapeutic target and test for metabolic syndrome
Cho et al. Effects of chitooligosaccharide lactate salt on sleep deprivation-induced fatigue in mice
Khan et al. Application of nanoparticles in oral hygiene
Haider Iqbal et al. Antioxidants: A Brief Review
Li et al. Conditioned taste aversion as instrumental punishment.
FR3024019A1 (fr) Complement alimentaire pour ameliorer le fonctionnement des cellules vivantes et procede associe
Russell A Study into the Biological Activity and Therapeutic Potential of Molecular Hydrogen and Oxyhydrogen Gases.
Idkaidek et al. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach
Qaid et al. Study of Vitamin C amount in pharmaceutical industries and its matching with manufacturer’s specifications in the prospectus for different companies
CN102309443B (zh) 一种小团簇水补锌口服液及其制备方法和应用
CN105596362A (zh) 能量水粉矿物质补充剂及激活方法
Bhatt et al. Acceptance of the Nanotechnology in the Food Industry for customer Satisfaction
Freye et al. ATC Malachlorite® for treatment of patients with acute Plasmodium falciparum infection: A pilot study incorporating 500 patients in the rural area of Cameroon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22709366

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22709366

Country of ref document: EP

Kind code of ref document: A1